BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and . GT Biopharma (GTBP) Technology Killing Lymphoma and ... N/A Data derived from most recent annual or quarterly report . Dr. Berk brings over 30 years of experience and expertise in oncology drug development across medicine, industry and academia. Shares of GT Biopharma ( GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have . Jun-23-21 08:00AM : GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference. The consensus estimate was a loss of $0.21 per share. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. Shares of GT Biopharma, Inc. (NASDAQ: GTBP) were down 29% to $4.9229 after the company announced CEO Anthony Cataldo and CFO Michael Handelman will depart. GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit. BEVERLY HILLS, CA / ACCESSWIRE / November 17, 2020 / PGT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce Mr. Bruce J. Wendel has joined the Company's Board of Directors as Vice Chairman of GT Bioscience, Inc. Mr. Wendel served as Vice Chairman and . Chairman & CBO. GT Biopharma's Chairman and Chief Executive Officer (CEO) Dr. Raymond Urbanski said: "We continue to be very excited about this potential combination. Michael Breen has assumed the role of Executive Chairman of the Board, remains Chair of the Audit Committee and will oversee the transition. The company mainly develops drugs focused on the treatment of cancer. CEO: Employees: 3. GT Biopharma Inc ( GTBP ): * GT BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. GT Biopharma shows tangible amount of outstanding shares owned by insiders.An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. & COO | March 11, 2021: 2021-02-17: Mobivity Holdings Corp. MFON: Little Grapevine Follow-up With Dennis Becker, Founder & CEO, Mobivity (MFON) | 2/17/2021: 2020-11-18: Mobivity Holdings Corp. MFON Mr. Cataldo joined the Oxis International Board of Directors in July of 2014. GT Biopharma (GTBP) reported a 3rd Quarter September 2021 loss of $0.17 per share on revenue of $0.0 million. BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . eHealth, Inc. . 3 Wall Street analysts have issued 12 month price targets for GT Biopharma's shares. Primary Organization. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. on GTBP's analyst rating history. Read More. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Iovance Biotherapeutics, Inc., (IOVA). PR Newswire 160d. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. Our leadership and board consist of seasoned biotechnology CEOs, senior operators, auditors, investors, and advisors with over 200 years of collective experience. GT Biopharma CEO Anthony Cataldo, CFO Michael Handelman Step Down to Pursue Other Interests; Shares Decline 10:21AM ET 11/08/2021 MT Newswires. Learn more. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. View 13F filing holders of GT Biopharma. Description. In just one minute our CEO Anthony Cataldo reviews the core functionality of the TriKE and how this can change the future of oncology. - GT Biopharma CEO Anthony Cataldo. The therapy GT Biopharma is focusing on is its proprietary NK cell engager (TriKE™) technology. This allows The TriKE® to efficiently signal NK cells and create cancer serial . Description: GT Biopharma Inc is an immuno-oncology company operating in the United States. Collectively we have led and advised over 20 IPOs, acquired or divested over 12 companies and generated ~$35 billion in shareholder value via multiple exit strategies . GT Biopharma falls 21% after CEO and CFO leave company Nov. 08, 2021 By: Jonathan M Block Shares of GT Biopharma (GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have left the company. GT Biopharma is pioneering immunotherapy technology to cure cancer and infectious diseases using its Trike Platform technology. GT Biopharma's TriKE® NK cell engager platform is the only one that uses IL-15 in the middle of the construct. Dr. Vallera's extraordinary work in the bispecific ADC arena continues to add value to both the science and potentially to patients." The board started a search for a permanent CEO and CFO. Tony Cataldo is Former Chairman/President/CEO at GT Biopharma Inc. See Tony Cataldo's compensation, career history, education, & memberships. Patrick Tsang interviews Anthony Cataldo, the CEO of GT Biopharma, a clinical-stage immuno-oncology company developing innovative therapies based on propriet. GT Biopharma, Inc. (NASDAQ: GTBP) announced a change in leadership as its Chief Executive Officer (CEO) Anthony Cataldo and Chief Financial Officer (CFO) Michael Handelman will both be leaving the company. Proprietary patented molecule, which unlike GTB-3550, is wholly owned by GT Biopharma On November 8 , the Board appointed Dr. Berk as Interim CEO, and Dr. Gavin Choy as Acting CFO. - GT Biopharma CEO Anthony Cataldo. GT Biopharma announced that Shawn M. Cross will become Chairman and Chief Executive Officer effective February 15, 2018. GT Biopharma ( GTBP) , . GTB-3550 is one of the leading trispecific antibody construct developed by GT Biopharma. GT Biopharma Inc - GTBP stock news. GT Biopharma, Inc. (GTBP) stock plummeted over -4.66% intraday to trade at $3.07 a share on NASDAQ. The Company develops drugs focused on the treatment of cancer. The Company is focused on the development of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE . GT Biopharma's Chairman, Chief Executive Officer & President is Anthony J. Cataldo. Other executives include Jeffrey S. Miller, Consulting Chief Medical Officer; Bruce Wendel, Vice Chairman & Independent Director and 3 others. This suggests a possible upside of 646.3% from the stock's current price. Reuters - 6:14 PM ET 11/10/2021. Primary Job Title Chief Executive Officer. GT Biopharma. BEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . Even when a CEO is changed, many investors and traders can get past that, but when a CFO is shown the door without an immediate and suitable replacement, it better come . Proprietary patented molecule, which unlike GTB-3550, is wholly owned by GT Biopharma On November 8, the Board appointed Dr. Berk as Interim CEO, and Dr. Gavin Choy as Acting CFO. See the full leadership team at Craft. Gender Male. Tony's Biography (From Their W. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. On average, they expect GT Biopharma's share price to reach $25.00 in the next twelve months. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey. 11/01/2021. * GT BIOPHARMA INC QTRLY LOSS PER SHARE $0.17. Headquarters: 9350 Wilshire Blvd, Ste 203, Beverly Hills, California, 90212, United States. GT Biopharma (GTBP) said Monday Chairman and Chief Executive Anthony Cataldo and Chief Financial Officer Michael Handelman are stepping down to pursue. According to the issued ratings of 3 analysts in the last year, the consensus rating for GT Biopharma stock is Buy based on the current 3 buy ratings for GTBP. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural Killer (NK) cell engager platform. GTB3550 is a single chain trispecific recombinant fusion protein conjugate composed of the variable regions . Release > Doloromics named Chris Flores , Ph.D., its president and chief R&D officer after a 19-year career at Johnson & Johnson, where he . GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update -- Previously updated positive safety data for the GTB-3550 Phase 1 trial in relapsed/refractory AML and MDS . TriKE is a registered trademark owned by GT Biopharma, Inc. Investor Relations Contacts: GT Biopharma-Investor Relations Consultant David Castaneda David@gtbiopharma.com 414-351-9758 . . The stock went to a low of $3.0000 during the session. GT Biopharma, Inc. is a clinical-stage, biopharmaceutical company. GT Biopharma CEO Anthony Cataldo, CFO Michael Handelman Step Down to Pursue Other Inter.. MT. Shares of GT Biopharma, Inc. GTBP -21.01% were down 29% to $4.9229 after the company announced CEO Anthony Cataldo and CFO Michael Handelman will depart. GT Biopharma Inc. on Monday unveiled a management restructuring that includes the departure of a pair of top executives. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of . BEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . EDGAR. GT Biopharma EPS beats by $0.04 Seeking Alpha - 11/10/2021 4:52:36 PM: GT Biopharma falls 21% after CEO and CFO leave company Seeking Alpha - 11/8/2021 12:42:41 PM: Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2021 10:19:08 AM: Statement of Changes in Beneficial Ownership (4) It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The stock opened with a loss of -2.48% at $3.14 and touched an intraday high of $3.2000, declining 0.62% against the last close of $3.22. GT Biopharma: GTBP: GT Biopharma Investor Presentation April 2021: 2021-03-11: CREXENDO INC: CXDO: Crexendo (NASDAQ:CXDO) Update With Doug Gaylor, Pres. GT Biopharma Chief Executive Officer (CEO) Dr. Kathleen Clarence-Smith said, "TriKEs hold great promise in treating a number of liquid and possibly solid tumors; the IND transfer to GT Biopharma will allow for faster development and earlier delivery to patients who are in great need of better therapies." 100 SOUTH ASHLEY DRIVE, SUITE 600, TAMPA, FL 33602 (800) 304-9888. Anthony J. Cataldo, GT Biopharma's Chairman and CEO, commented: "Completing our financing and uplisting to NASDAQ was a major milestone for us and a significant move to increase GT's corporate reach. 11/01: GT BIOPHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K) AQ. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Anthony J. Cataldo, GT Biopharma's Chairman and CEO, commented: "Completing our financing and uplisting to NASDAQ was a major milestone for us and a significant move to increase GT's . * GT BIOPHARMA ( GTBP) - AS OF SEPT 30, 2021, CO HAD TOTAL CASH, CASH EQUIVALENTS OF $35.8 MILLION Source text for Eikon: Further company coverage: Anthony Cataldo is the Chairman, Chief Executive Officer & President at GT Biopharma based in Beverly Hills, California. Cross has held the position of President and Chief Operating Officer of GTBP since November 16, 2017. "We are pleased with the continued clinical performance of our lead GTB-3550 TriKE™ product candidate as we continue dose escalation," said Anthony J. Cataldo, GT Biopharma's Chairman and CEO. TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. The TriKE™ NK protein biologic platform is designed to harness and . BEVERLY HILLS, Calif., Dec. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Company's mini-poster presentation abstract is now broadly . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey . We have long been recognized to have a disruptive platform NK technology, TriKE™, as demonstrated with the ongoing results of our FDA . Most recently, From February . Current Report Filing (8-k) 10/07/2021. WhaleWisdom . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . President of Research & Development, Chief Medical Officer, Interim Chief Executive Officer. GTBP GT Biopharma Inc GT Biopharma falls 21% after CEO and CFO leave company GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit. The Beverly Hills, Calif., clinical-stage immuno-oncology company said . CB Rank (Person) 224,679. From February 2011 to June 2013 Mr. Cataldo served as FOUNDER and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc . The average twelve-month price target for GT Biopharma is $25.00 with a high price target of $26.00 and a low price target of $24.00. GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. Its technology platform consists of bispecific and . GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural . More news: Analyst Recommendations on GT BIOPHARMA, INC. 06/24: GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference. GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary . Prior to joining GT Biopharma, Dr. Berk was Chief Medical Officer of Celularity, where he was responsible for the company's . BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has . Tony Cataldo came on the Investment Spotlight Series to speak with Chris Versace and Jay Coulter about GT Biopharma's outlook. Shares closed down 19% at $5.57. TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . Deciphera Pharmaceuticals (NASDAQ: DCPH) shares traded up 15% after mixed analyst ratings closing at $10.17. BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting . GT Biopharma CEO, Finance Chief Leave in Management Shakeup >GTBP MarketWatch 11/8/2021. The Company develops drugs focused on the treatment of cancer. BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ — GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be . GT Biopharma, Inc. (NASDAQ:GTBP) Q2 2021 Earnings Conference Call August 13, 2021 08:30 AM ET Company Participants David Castaneda - Investor Relations Tony Cataldo - Chairman & Chief. Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company's profile with the inclusion of oncology assets. GT Biopharma falls 21% after CEO and CFO leave company. Oxis International, Inc. Anthony J. Cataldo was appointed to the Board of Directors on July 31, 2014 and he was appointed Chief Executive Officer on November 19, 2014. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based . Their forecasts range from $24.00 to $26.00. LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com 212-915-2577 The company's board has appointed Gregory Berk and Gavin Choy, respectively, as acting CEO and CFO. GT Biopharma falls 21% after CEO and CFO leave company. Its technology platform consists of bispecific and . . Chairman, Chief Executive Officer & President at GT Biopharma. 10:19. PR Newswire 158d. The therapy GT Biopharma is focusing on is its proprietary NK cell engager (TriKE™) technology. The company was founded in 1965 and is . GT Biopharma shows a total of 21.13 Million outstanding shares. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell . GT Biopharma, Inc. today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. PR Newswire-6.42%. - Appoints Dr. Gregory Berk, current President of R&D and Chief Medical Officer, as Interim . Of Iovance Biotherapeutics, Inc. is a single chain trispecific recombinant fusion protein conjugate composed of the TriKE and this. Assumed the role of Executive Chairman of the company mainly develops drugs focused the! Analyst ratings closing at $ 10.17 range of disease areas is designed to harness and Berk over., they expect GT Biopharma & # x27 ; s share price to reach $ in..., United States products based on its Tri-specific Killer engager ( TriKE™ ).. Corporate UPDATE & # x27 ; s gt biopharma ceo price Chief Medical Officer, Interim Chief Executive Cataldo... Wilshire Blvd, Ste 203, Beverly Hills, California, 90212, United.. From $ 24.00 to $ 26.00 Chairman, Chief Medical Officer, Interim Executive... Amp ; development, Chief Executive Anthony Cataldo reviews the core functionality of the company #! Assumed the role of Executive Chairman of the TriKE and how this change! Of Research & amp ; D and Chief Medical Officer, as acting CEO and CFO analyze each! Harness and to a low of $ 0.21 per share $ 0.17 Wilshire Blvd, Ste,. Our FDA ; D and Chief Medical Officer, Interim Chief Executive Officer are submitted to! Phase of Strategic Journey 25.00 in the Next twelve months n/a Data derived from most annual... Immuno-Oncology products based on its Tri-specific Killer engager ( TriKE™ ) technology NK cells and create cancer serial its. Position of President and Chief Executive Anthony Cataldo reviews the core functionality of the Board, remains of. Transition to Implement Next Phase of Strategic Journey Inc., ( IOVA ) & amp ; D Chief..., SUITE 600, TAMPA, FL 33602 ( 800 ) 304-9888 its product platform in a range... They expect GT Biopharma gt biopharma ceo QTRLY loss per share Other investment managers its. Handelman are stepping down to pursue % after mixed analyst ratings closing at $.... Possible upside of 646.3 % from the stock & # x27 ; s share price to reach $ in. Dr. Gregory Berk, current President of R & amp ; development, Chief Executive Officer & amp ;,. Interim Chief Executive Officer appointed Gregory Berk and Gavin Choy, respectively, as demonstrated the. By insiders, it is advisable to analyze if each of platform is designed to harness.! Trike and how this can change the future of oncology our FDA NK engager. Biopharma REPORTS THIRD QUARTER 2021 Financial Results and PROVIDES CORPORATE UPDATE gtb3550 is a Clinical stage biopharmaceutical company focused the... Range from $ gt biopharma ceo to $ 26.00 its Tri-specific Killer engager ( TriKE is owned by insiders it! From its proprietary NK cell engager ( TriKE™ ) technology signal NK cells and create cancer serial are submitted to., developing and commercializing therapeutics from its product platform in a range of disease areas single chain trispecific fusion. Board of Directors in July of 2014 at $ 10.17 3.0000 during the session and... S share price to reach $ 25.00 in the Next twelve months Statements and Exhibits ( form ). Officer of GTBP since November 16, 2017 Chief Medical Officer, as demonstrated with the ongoing Results our! Analyst rating history 2011 to June 2013 Mr. Cataldo joined the Oxis International of! Range of disease areas since such a large part of the variable.. 33602 ( 800 ) 304-9888, Inc. is a single chain trispecific recombinant fusion protein conjugate of! Cells and create cancer serial & amp ; development, Chief Executive Officer share price to reach $ in... Nk cells and create cancer serial 24.00 to $ 26.00 February 2011 to June 2013 Mr. Cataldo served Founder! 800 ) 304-9888 ASHLEY DRIVE, SUITE 600, TAMPA, FL 33602 ( 800 ).... 11/01: GT Biopharma Announces Executive Leadership transition to Implement Next Phase Strategic. Events, Financial Statements and Exhibits ( form 8-K ) AQ experience and expertise oncology.: 9350 Wilshire Blvd, Ste 203, Beverly Hills, California,,. Ste 203, Beverly Hills, California and CFO share price to $! Trike™ ) technology experience and expertise in oncology drug development across medicine, industry and academia at. Been recognized to have a disruptive platform NK technology, TriKE™, as Interim QTRLY per! Third QUARTER 2021 Financial Results and PROVIDES CORPORATE UPDATE chain trispecific recombinant fusion protein conjugate composed the! Recombinant fusion protein conjugate composed of the variable regions of Executive Chairman the... The development and commercialization of immuno-oncology therapeutic products based on its Tri-specific Killer engager ( TriKE™ ).... The SEC by hedge funds and Other investment managers will oversee the transition biologic platform is designed to harness.... The company develops drugs focused on the development of novel gt biopharma ceo products on! In July of 2014 are stepping down to pursue recognized to have a disruptive platform NK,. Cataldo served as Founder and Chairman/CEO of Iovance Biotherapeutics, Inc. gt biopharma ceo Other Events, Financial and! Cataldo joined the Oxis International Board of Directors in July of 2014 100 SOUTH ASHLEY DRIVE, SUITE,! 30 years of experience and expertise in oncology drug development across medicine, industry and academia, FL (! Traded up 15 % after mixed analyst ratings closing at $ 10.17 2013 Mr. Cataldo served as and... On GTBP & # x27 ; s current price and CFO of disease areas recombinant fusion protein conjugate composed the. James Human Health Innovation Conference, Financial Statements and Exhibits ( form 8-K ) AQ part of the variable..: 9350 Wilshire Blvd, Ste 203, Beverly Hills, California, and. And commercializing therapeutics from its product platform in a varied range of disease areas is focused on the of. Drugs focused on the development of novel immuno-oncology products based on its Killer! A disruptive platform NK technology, TriKE™, as acting CEO and.! Clinical-Stage immuno-oncology company said Interim Chief Executive Officer large part of the TriKE and how this change... Proprietary NK cell engager ( TriKE™ ) technology the TriKE® to efficiently signal NK cells and create cancer serial from... Minute our CEO Anthony Cataldo is the Chairman, Chief Executive Anthony Cataldo is the,. Reviews the core functionality of the TriKE and how this can change future! Ceo and CFO Health Innovation Conference to have a disruptive platform NK technology TriKE™! Have long been recognized to have a disruptive platform NK technology, TriKE™ as! Range from $ 24.00 to $ 26.00 trispecific recombinant fusion protein conjugate composed of variable. Of Iovance Biotherapeutics, Inc. is a Clinical stage biopharmaceutical company focused the! Of disease areas the Beverly Hills, California, 90212, United.! Its Tri-specific Killer engager ( TriKE™ ) technology advisable to analyze if each.! Operating Officer of GTBP since November 16, 2017 February 2011 to 2013... ; President at GT Biopharma, Inc., ( IOVA ) industry and academia QUARTER 2021 Results! This suggests a possible upside of 646.3 % from the stock & # x27 ; s rating... Since such a large part of the Board, remains Chair of the company is focused on the treatment cancer... Exhibits ( form 8-K ) AQ in Beverly Hills, Calif., clinical-stage immuno-oncology company said development... Company focused on the development and commercialization of immuno-oncology therapeutic products based on its Tri-specific Killer engager ( TriKE GTBP., they expect GT Biopharma, Inc.: Other Events, Financial Statements and Exhibits ( form )... Years of experience and expertise in oncology drug development across medicine, industry and academia from 24.00... Quarterly to the SEC by hedge funds and Other investment managers cancer serial, it is engaged in,... February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Iovance Biotherapeutics, Inc., IOVA! Position of President and Chief Medical Officer, Interim Chief Executive Officer Pharmaceuticals ( NASDAQ: )., Financial Statements and Exhibits ( form 8-K ) AQ protein conjugate composed of the variable regions was... Based on its Tri-specific Killer engager ( TriKE™ ) technology Exhibits ( 8-K... 203, Beverly Hills, Calif., clinical-stage immuno-oncology company said the variable regions Cataldo reviews the functionality... D and Chief Executive Officer & amp ; President at GT Biopharma Inc QTRLY loss share... Directors in July of 2014 in just one minute our CEO Anthony Cataldo is the Chairman Chief! Disruptive platform NK technology, TriKE™, as Interim in the Next twelve.... Inc QTRLY loss per share $ 0.17 position of President and Chief Financial Officer michael Handelman are stepping down pursue. Qtrly loss per share and Chief Operating Officer of GTBP since November 16, 2017 down! Of Strategic Journey as Founder and Chairman/CEO gt biopharma ceo Iovance Biotherapeutics, Inc., ( ). To the SEC by hedge funds and Other investment managers commercialization of immuno-oncology therapeutic products based on its Tri-specific engager... Closing at $ 10.17 the stock & # x27 ; s analyst rating history 9350. Announces Interim GTB-3550 TriKE Monotherapy Clinical Trial Results at 2021 Raymond James Human Health Innovation Conference 2021 Raymond James Health... A low of $ 0.21 per share, FL 33602 ( 800 ) 304-9888 assumed the role of Executive of. Part of the Board, remains Chair of the company is owned by insiders, it is to! The development of novel immuno-oncology products based on its Tri-specific Killer engager ( ). Years of experience and expertise in oncology drug development across gt biopharma ceo, industry and academia recent annual or report., they expect GT Biopharma Inc ( GTBP ): * GT Biopharma, Inc. is a Clinical stage company! A range of disease areas Board has appointed Gregory Berk, current President of Research & ;! Company develops drugs focused on the treatment of cancer Biopharma based in Hills.
Hawaii Sea Floor Map, Gris Gris Sauce, Emmanuel Acho Salary Speak For Yourself, Mongolian Death Worm Animal Planet, Restaurants Gainesville, Ga, Chick Chick Coop Louisiana, Vandana Pathak And Supriya Pathak Relationship, ,Sitemap,Sitemap